|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-02
|
$520,564
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
5P30CA013330-45
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Tumor expressed B7x accelerates disease and is a novel target for immunotherapy
|
5F31CA183493-04
|
$49,044
|
OHAEGBULAM, KIM
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Interferon-gamma limits the effectiveness of peptide vaccines for cancer
|
5R01CA157303-06
|
$294,616
|
CELIS, ESTEBAN
|
AUGUSTA UNIVERSITY
|
|
PTEN, Tregs and MDSCs in the tumor microenvironment
|
1R01CA211229-01A1
|
$347,700
|
MUNN, DAVID
|
AUGUSTA UNIVERSITY
|
|
A CD47-blocking oncolytic vaccinia virus for cancer therapy
|
5F30CA203270-02
|
$44,044
|
CAO, FELICIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
REGULATION OF UVEAL MELANOMA CELL FATE BY THE PKC PATHWAY VIA MITF
|
5R01CA193321-03
|
$362,569
|
MITSIADES, NICHOLAS
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S1
|
$118,333
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S2
|
$118,875
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S3
|
$122,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S4
|
$250,002
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-11
|
$3,253,119
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Cbx-3/HP-1gamma deficiency confers anti-tumor immunity
|
5R21CA198263-02
|
$225,765
|
THAI, TO-HA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Defining driver tumor-suppressors for melanoma using the zebrafish
|
5K99CA201465-02
|
$171,990
|
ABLAIN, JULIEN
|
BOSTON CHILDREN'S HOSPITAL
|
|
Cancer Deep Phenotype Extraction from Electronic Medical Records
|
7U24CA184407-05
|
$586,963
|
SAVOVA, GUERGANA
|
BOSTON CHILDREN'S HOSPITAL
|
|
Cancer biology in the zebrafish
|
5R01CA103846-15
|
$373,081
|
ZON, LEONARD
|
BOSTON CHILDREN'S HOSPITAL
|
|
Development of a novel cell-based immune therapy using Nanoparticles and natural IgM-producing phagocytic B cells
|
5R21CA205415-02
|
$186,807
|
ZHONG, XUEMEI
|
BOSTON MEDICAL CENTER
|
|
Molecular connections among UV exposure, red hair, nevi and melanoma
|
5R01CA193913-02
|
$376,294
|
CUI, RUTAO
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Why red-haired individuals are so prone to developing melanoma
|
5R01CA196896-03
|
$374,464
|
CUI, RUTAO
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
PAX3 pathways in melanoma
|
5R01CA184001-04
|
$376,389
|
LANG, DEBORAH
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Targeting Transcriptional Co-repressor CoREST Complex in Melanoma
|
1R01CA212639-01A1
|
$369,038
|
RYU, BYUNGWOO
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Elucidating the Regulation and Function of the NF1 tumor suppressor
|
5R01CA111754-12
|
$316,635
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Functional Analysis of Galectin-1 Ligands in Melanoma Progression
|
5R01CA173610-05
|
$361,558
|
DIMITROFF, CHARLES
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Role of melanoma-PD-1 in cancer progression
|
1R01CA190838-01A1
|
$395,502
|
SCHATTON, TOBIAS
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Coordinating tumor differentiation and immune suppression with the metabolic state and treatment outcome
|
1R01CA207982-01A1
|
$411,278
|
WIDLUND, HANS
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Exploring mechanisms to increase cancer cell antigenicity by modulating lineage-specific transcription in tumors
|
1R03CA212987-01A1
|
$78,830
|
WIDLUND, HANS
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
(PQ3) The role of damaged DNA in inter-individual variation of tumor immunity
|
5R01CA208756-02
|
$518,165
|
HACOHEN, NIR
|
BROAD INSTITUTE, INC.
|
|
Targeting vulnerabilities of therapy-resistant cancer cell states with small molecules
|
1U01CA217848-01
|
$1,146,075
|
SCHREIBER, STUART
|
BROAD INSTITUTE, INC.
|
|
Steady states and cellular transitions associated with carcinogenesis and tumor progression
|
1U01CA217655-01
|
$644,276
|
HEATH, JAMES
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Nanosystems Biology Cancer Center
|
5U54CA199090-03
|
$2,403,338
|
HEATH, JAMES
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
In vivo imaging of single circulating cells
|
5R01CA186567-06
|
$717,674
|
WANG, LIHONG
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Targeting BPTF in the Therapy of BRAF-mutant Melanoma
|
1R01CA215755-01
|
$614,787
|
KASHANI-SABET, MOHAMMED
|
CALIFORNIA PACIFIC MED CTR RES INSTITUTE
|
|
PHIP as a Biomarker of Triple-Negative Melanoma
|
5R01CA175768-04
|
$424,835
|
KASHANI-SABET, MOHAMMED
|
CALIFORNIA PACIFIC MED CTR RES INSTITUTE
|
|
Targeting the developmental pathways Notch and ERBB for melanoma therapy
|
5R01CA177652-04
|
$18,933
|
BEDOGNI, BARBARA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S1
|
$118,875
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S2
|
$60,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S3
|
$200,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S4
|
$145,821
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-27
|
$4,895,515
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
3U10CA180853-04S1
|
$76,498
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-04
|
$1,188,450
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology
|
1U01CA218292-01
|
$616,764
|
STEINMETZ, NICOLE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Development of GIFT4: a B cell focused immunotherapy for cancer
|
1R44CA217365-01
|
$999,088
|
GUYRE, PAUL
|
CELDARA MEDICAL, LLC
|
|
The Development of Novel Mechanistically-based APE/Ref-1 Redox Inhibitors
|
5K08CA179084-04
|
$113,074
|
YANG, SUN
|
CHAPMAN UNIVERSITY
|
|
Effect of different MRgHIFU approaches on anti-tumor responses
|
5R03CA201918-02
|
$78,000
|
JANSSEN, EDITH
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Proteomics of Metastatic and Non-Metastatic Uveal Melanoma
|
1R21CA209500-01A1
|
$206,843
|
CRABB, JOHN
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Role of MIF in myeloma bone homing and drug response
|
1R01CA211073-01
|
$362,569
|
YI, QING
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Cancer Center Support Grant
|
3P30CA013696-43S1
|
$120,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S2
|
$60,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S3
|
$118,652
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|